NEW
YORK, July 6, 2022 /PRNewswire/ -- The Gross Law
Firm issues the following notice to shareholders of Spero
Therapeutics, Inc..
Shareholders who purchased shares of SPRO during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/spero-therapeutics-inc-loss-submission-form/?id=29518&from=4
CLASS PERIOD: October 28,
2021 to May 2, 2022
ALLEGATIONS: The complaint alleges that during the class
period, Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (i) the data submitted
in support of the New Drug Application ("NDA") for the Company's
product candidate, Tebipenem HBr, were insufficient to obtain
approval from the U.S. Food and Drug Administration ("FDA"); (ii)
accordingly, it was unlikely that the FDA would approve the
Tebipenem HBr NDA in its current form; (iii) the foregoing would
necessitate a significant workforce reduction and restructuring of
Spero's operations; and (iv) as a result, the Company's public
statements were materially false and misleading at all relevant
times.
DEADLINE: July 25, 2022
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/spero-therapeutics-inc-loss-submission-form/?id=29518&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of SPRO during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is July 25, 2022. There is no cost or
obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law Firm is
committed to ensuring that companies adhere to responsible business
practices and engage in good corporate citizenship. The firm seeks
recovery on behalf of investors who incurred losses when false
and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-spero-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-july-25-2022--nasdaq-spro-301580910.html
SOURCE The Gross Law Firm